Gt Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
RainForest Partners, LLC has filed a Schedule 13G, reporting beneficial ownership of 180,258 shares of GT Biopharma, Inc. common stock, representing 9.99% of the class, with an explicit ownership restriction.
NASDAQ
SCHEDULE 13G/A: Bristol Entities Maintain Significant Passive Stakes in GT Biopharma, Amending Ownership Disclosure
Bristol Investment Fund, Ltd. and Bristol Capital, LLC have filed an amendment to their Schedule 13G, disclosing their continued passive beneficial ownership in GT Biopharma, Inc.'s common stock.
NASDAQ
Five Narrow Lane LP has reported a passive beneficial ownership of 9.99% in GT Biopharma, Inc., holding 253,388 shares of common stock.